Edition:
United States

Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

35.03USD
11:08am EST
Change (% chg)

$-0.23 (-0.67%)
Prev Close
$35.26
Open
$35.31
Day's High
$35.34
Day's Low
$34.83
Volume
443,058
Avg. Vol
708,856
52-wk High
$58.99
52-wk Low
$30.90

NVO.N

Chart for NVO.N

About

Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company's business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1),... (more)

Overall

Beta: 0.80
Market Cap(Mil.): $69,571.76
Shares Outstanding(Mil.): 2,012.56
Dividend: 0.45
Yield (%): 2.57

Financials

  NVO.N Industry Sector
P/E (TTM): 16.60 30.14 30.77
EPS (TTM): 2.12 -- --
ROI: 81.12 15.85 15.23
ROE: 88.79 16.96 16.56

Novo Nordisk seeks EU and U.S. approval for new diabetes treatment

OSLO Danish Novo Nordisk said on Monday it has filed for the European Union and the U.S. approval of semaglutide to treat adults with type 2 diabetes.

Dec 05 2016

Novo Nordisk reports Tresiba insulin achieves target in study

COPENHAGEN Novo Nordisk's long-acting insulin blockbuster Tresiba has a safe cardiovascular profile and reduces episodes of severely low blood glucose levels in patients with type 2 diabetes, the Denmark-based company said on Tuesday.

Nov 29 2016

UPDATE 1-Novo Nordisk reports Tresiba insulin achieves target in study

COPENHAGEN, Nov 29 Novo Nordisk's long-acting insulin blockbuster Tresiba has a safe cardiovascular profile and reduces episodes of severely low blood glucose levels in patients with type 2 diabetes, the Denmark-based company said on Tuesday.

Nov 29 2016

Novo Nordisk says Tresiba insulin achieves target in DEVOTE study

COPENHAGEN, Nov 29 Novo Nordisk's long-acting insulin blockbuster Tresiba has a safe cardiovascular profile in patients with type 2 diabetes, results released by the company on Tuesday showed.

Nov 29 2016

UPDATE 1-TDC loses major contract with Novo Nordisk to Telenor

COPENHAGEN, Nov 29 Danish telecoms group TDC has lost a major contract in Denmark after one of the country's biggest employers, Novo Nordisk, said it chose Norway's Telenor as its telecoms supplier.

Nov 29 2016

TDC loses major contract with Novo Nordisk to Telenor

COPENHAGEN, Nov 29 Danish telecoms group TDC has lost a major contract in Denmark after one of the country's biggest employers, Novo Nordisk, said it chose Norway's Telenor as its telecoms supplier.

Nov 29 2016

Novo, Sanofi go head to head as FDA clears new diabetes drugs

Rivals Novo Nordisk and Sanofi have won U.S. approval for new combination drugs to treat diabetes, sparking a fresh battle for sales in a fiercely competitive market.

Nov 22 2016

UPDATE 2-Novo, Sanofi go head to head as FDA clears new diabetes drugs

* Companies to sell two-drug products at discount (Adds detail on pricing, quote from Novo Nordisk executive)

Nov 22 2016

BRIEF-Novo Nordisk to offer discount on Xultophy in U.S.

* Says it will begin negotiations with buyers of its combination diabetes drug Xultophy in the United States by offering a 20 percent discount to the combined price of Tresiba and Victoza.

Nov 22 2016

How drug price pressure helped sink Novo's insulin pill

LONDON Commercial rather than technical hurdles ultimately torpedoed Novo Nordisk's bid to make an oral form of insulin, its chief executive said on Wednesday, underscoring the impact of U.S. price pressure on the world's top insulin supplier.

Nov 16 2016

Competitors

  Price Chg
Sanofi SA (SASY.PA) €74.59 -0.96
Eli Lilly and Co (LLY.N) $66.72 -1.08

Earnings vs. Estimates